Cleared Traditional

K211156 - CONVIVO In Vivo Pathology Suite (FDA 510(k) Clearance)

Class II Neurology device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K211156 · Carl Zeiss Meditec, AG · Neurology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Dec 2021
Decision
254d
Days
Class 2
Risk

K211156 is an FDA 510(k) clearance for the CONVIVO In Vivo Pathology Suite. Classified as System, Image Processing, Radiological within the LLZ classification (a category encompassing advanced image processing and PACS-adjacent software), Class II - Special Controls.

Submitted by Carl Zeiss Meditec, AG (Jena, DE). The FDA issued a Cleared decision on December 29, 2021 after a review of 254 days - an extended review cycle.

This device falls under the Neurology FDA review panel, regulated under 21 CFR 892.2050 - the FDA neurology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Incremental AI imaging tool. Moderate-to-high equivalence dependency. Overall, this clearance reflects a predicate-aligned approval typical of modern AI radiology extensions - not a novel clinical breakthrough, but a validated iteration within an established regulatory category.

View all Carl Zeiss Meditec, AG devices

Submission Details

510(k) Number K211156 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received April 19, 2021
Decision Date December 29, 2021
Days to Decision 254 days
Submission Type Traditional
Review Panel Neurology (NE)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
106d slower than avg
Panel avg: 148d · This submission: 254d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code LLZ System, Image Processing, Radiological
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 892.2050
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Neurology devices follow this clearance model.

Regulatory Consultant

Carl Zeiss Meditec, Inc.
Maria Golovina

The regulatory consultant manages the 510(k) submission process on behalf of the applicant - coordinating technical documentation, predicate strategy and FDA communications. Identifying the consultant behind a submission is a key signal for competitive regulatory intelligence.

Regulatory Peers - LLZ System, Image Processing, Radiological

All 2262
Devices cleared under the same product code (LLZ) and FDA review panel - the closest regulatory comparables to K211156.
LungPoint Virtual Bronchoscopic Navigation (VBN) Software
K260009 · Broncus Medical, Inc. · Apr 2026
CCI PACS VIEWER (PACS-US-001)
K254237 · CliniComp, Intl. · Apr 2026
ARTICOR planner
K252195 · Artiness S.R.L · Mar 2026
TheraSphere 360™ Y-90 Management Platform
K260479 · Boston Scientific Corporation · Mar 2026
Aeka Imaging
K253111 · Good Methods Global, Inc. · Mar 2026
Mimics Thoracic Planner
K251964 · Materialise NV · Mar 2026